From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
Pharmacokinetic data
Protein binding 90-94%
Biological half-life 12 hours
CAS Number 63590-64-7
ATC code G04CA03 (WHO)
PubChem CID 5401
DrugBank APRD00667
Synonyms [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-tetrahydrofuran-2-yl-methanone
Chemical data
Formula C19H25N5O4
Molar mass 387.433 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Terazosin (marketed as Hytrin) is a selective alpha 1 antagonist used for treatment of symptoms of an enlarged prostate (BPH). It also acts to lower the blood pressure, and is therefore a drug of choice for men with hypertension and prostate enlargement.

It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.

Most common side effects include dizziness, drowsiness, headache, constipation, loss of appetite, fatigue, nasal congestion or dry eyes, but they generally go away after only a few days of use. Therapy should always be started with a low dose to avoid first dose phenomenon.[1] Sexual side effects are rare, but may include priapism or erectile dysfunction.


  1. Hytrin (Terazosin Hcl) drug warnings and precautions - prescription drugs and medications at RxList


fr:Térazosine id:Terazosin it:Terazosina